Abstract YO18
Case summary
Case Details - A 47-year-old female, a known case of multicentric Glioblastoma multiforme (grade four) who had received concurrent chemoradiotherapy followed by palliative Temozolomide on tapering doses of Levetiracetam and had been commenced on Phenytoin presented (during the peak of the second wave of Pandemic) with complaints of new-onset maculopapular lesions involving legs, arms, and lower back. She subsequently developed a worsening Rash with the development of vesico-bullous lesions, oral mucosal lesions, acral involvement, and systemic symptoms (Fever) 2 days later. Arrangements were made to obtain a Tele Dermatology consult (from a Private setting) following which a diagnosis of SJS TENS Overlap was made. A consult with the Medical Oncology department was sought in order to provide ICU admission which was refused. She was subsequently admitted under Palliative Medicine after obtaining high-risk consent. Her lesions regressed with supportive management comprising Cyclosporin, and intravenous antibiotics, however, her general condition deteriorated. She was discharged as she had expressed a wish to meet her mother (at home). However, she was unable to obtain a fitness for Air travel. She was re-admitted and re-started on supportive treatment (symptom-directed medications via intravenous route). A subcutaneous line was inserted in the anterior chest wall and pre-filled syringes containing essential pain medication, anti-seizure medication (sc bolus levetiracetam), and dexamethasone for three days were provided to the Patient’s husband who had volunteered to take her back home via Train.
Discussion - Important Issues included Logistical - Lack of infrastructure, Medical - use of boluses of subcutaneous medication at end of life (without syringe drivers).
Conclusion - Practical Issues related to Travel, Finances, and Continuity of care may assume more importance than Spirituality underlining the importance of formulating a comprehensive management plan most suited to the Patient and their Family members.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
450P - Are grade III well-differentiated neuroendocrine tumours a unique clinic-pathological entity?
Presenter: Jahnavi Kalvala
Session: Poster viewing 06
451P - The activity and safety of anlotinib combined with chemotherapy for patients with desmoid tumor: A retrospective study in a single institution
Presenter: Peng Zhang
Session: Poster viewing 06
452P - Medical and paramedical students’ awareness of environmental risk factors for cancer
Presenter: Mostafa Behery
Session: Poster viewing 06
453P - Relationship between Interleukin-6 Levels (IL-6) and COVID-19 vaccination status in cancer patients at Dr. Moewardi General Hospital, Indonesia
Presenter: Rico Hutabarat
Session: Poster viewing 06
454P - To study the prevalence of lower limb deep vein thrombosis in patients who present with stage III/IV solid tissue malignancies in Indian patients
Presenter: Oshin Suri
Session: Poster viewing 06
455P - Succinate dehydrogenase deficient GIST: Case series and review of literature from a tertiary care centre in India
Presenter: Akhil Santhosh
Session: Poster viewing 06
456P - Outcomes of COVID-19 infection in cancer patients: A single center study
Presenter: Sindhu G
Session: Poster viewing 06
457P - The effect of Interleukin-6 (IL-6) on malignancy in COVID-19 patients in Dr. Moewardi General Hospital Surakarta
Presenter: Meirisa Ardianti
Session: Poster viewing 06
458P - A real-world depiction of difficulties in applicability of IO regimens into clinical practice in metastatic setting
Presenter: Sharat Chandra Goteti
Session: Poster viewing 06
460P - The role of fluorescence-based cell-free DNA assay for detection of cancer by comparing patients with and without cancer
Presenter: Jae-Joon Kim
Session: Poster viewing 06